Discussion about this post

User's avatar
@abnheel's avatar

Fascinating. I had no idea. My background is in biotech (sales and marketing side) and you’re right, that path to Phase 1 clinical trials is loaded with landmines, roadblocks, and obstacles that prevents countless projects from ever getting off the ground. Number of compounds out there with potential are countless but the way the system is set up now, risk is avoided in exchange for projects that are considered more likely to succeed but not necessarily a significant advancement in science. How many patients will never get treatment from a game-changing drug because the funding for it was never there to bring it to fruition. Instead, the safe bet for VC and pharma is to just tweak an existing proven compound, file with regulatory, and extend a patent on a drug that doesn’t really move the needle vs what could have been with an entirely different class.

Expand full comment
DeGen Tiger Management's avatar

This is pretty amazing. Future app I can think of.

Having a rare genetic disorder. However, outcomes are minor and only 1-2M people have it worldwide. So no funding, few specialists, and no cure.

This would allow you to create an "Disorder" Dao. And get funding together from thousands in same situation.

Expand full comment
17 more comments...

No posts